Table 1.
Proportions of responders to pneumococcal polysaccharide and tetanus toxoid vaccines (week 8; per-protocol population)
| All patients* | Patients 18–50 years old | Patients 51–64 years old | ||||
|---|---|---|---|---|---|---|
| Proportions of responders to ≥6 of 12 anti-pneumococcal antibody serotypes | ||||||
| MTX n=24 |
TCZ (8 mg/kg)+MTX n=50 |
MTX n=9 |
TCZ (8 mg/kg)+MTX n=18 |
MTX n=15 |
TCZ (8 mg/kg)+MTX n=32 |
|
| Responders, n (%) (95% CI) |
17 (70.8) (52.6 to 89.0) |
30 (60.0) (46.4 to 73.6) |
7 (77.8) (50.6 to 100.0) |
12 (66.7) (44.9 to 88.4) |
10 (66.7) (42.8 to 90.5) |
18 (56.3) (39.1 to 73.4) |
| Proportions of responders to tetanus toxoid vaccine | ||||||
| MTX n=23 |
TCZ (8 mg/kg)+MTX n=50 |
– | – | – | – | |
| Responders, n (%) (95% CI) |
9 (39.1) (19.2 to 59.1) |
21 (42.0) (28.3 to 55.7) |
– | – | – | – |
| Patients with x-fold increases in anti-tetanus toxoid antibody levels† | ||||||
| ≥2-fold, n (%) | 15 (65.2) | 36 (72.0) | – | – | – | – |
| ≥4-fold, n (%) | 9 (39.1) | 21 (42.0) | – | – | – | – |
MTX, methotrexate; TCZ, tocilizumab.
*Patients with evaluable data.
†Patients in the ≥4-fold group are also included in the ≥2-fold group.